Search Results

There are 28507 results for: content related to: Preferences for antimuscarinic therapy for overactive bladder

  1. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial

    BJU International

    Volume 107, Issue 9, May 2011, Pages: 1432–1440, Steven A. Kaplan, Tim Schneider, Jenelle E. Foote, Zhonghong Guan, Martin Carlsson and Jason Gong

    Article first published online : 21 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09640.x

  2. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study

    BJU International

    Volume 107, Issue 4, February 2011, Pages: 603–611, Jean-Jacques Wyndaele, Evan R. Goldfischer, Jon D. Morrow, Jason Gong, Li-Jung Tseng and Myung-Soo Choo

    Article first published online : 22 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09587.x

  3. Scientific Programme, 42nd Annual Meeting of the International Continence Society (ICS) 15 – 19 October 2012, Beijing, China

    Neurourology and Urodynamics

    Volume 31, Issue 6, August 2012, Pages: 709–1102,

    Article first published online : 10 JUL 2012, DOI: 10.1002/nau.22287

  4. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

    International Journal of Clinical Practice

    Volume 65, Issue 4, April 2011, Pages: 487–507, S. A. Kaplan, C. G. Roehrborn, P. Abrams, C. R. Chapple, T. Bavendam and Z. Guan

    Article first published online : 7 JAN 2011, DOI: 10.1111/j.1742-1241.2010.02611.x

  5. Which anticholinergic drug for overactive bladder symptoms in adults

    Intervention Review

    The Cochrane Library

    Priya Madhuvrata, June D Cody, Gaye Ellis, G Peter Herbison and E. Jean C Hay-Smith

    Published Online : 18 JAN 2012, DOI: 10.1002/14651858.CD005429.pub2

  6. ICS-IUGA 2010 Scientific Programme, Wednesday 25th August 2010

    Neurourology and Urodynamics

    Volume 29, Issue 6, August 2010, Pages: 805–1255,

    Article first published online : 19 JUL 2010, DOI: 10.1002/nau.20973

  7. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration

    BJU International

    Volume 106, Issue 9, November 2010, Pages: 1332–1338, Christopher R. Chapple, Sender Herschorn, Paul Abrams, Joseph T. Wang, Marina Brodsky and Zhonghong Guan

    Article first published online : 24 MAY 2010, DOI: 10.1111/j.1464-410X.2010.09359.x

  8. Scientific Programme, 43rd Annual Meeting of the International Continence Society (ICS) 26 – 30 August 2013, Barcelona, Spain

    Neurourology and Urodynamics

    Volume 32, Issue 6, August 2013, Pages: 507–932,

    Article first published online : 8 JUL 2013, DOI: 10.1002/nau.22472

    Corrected by:

    Erratum: Erratum re: ICS abstract book. Abstract 207

    Vol. 32, Issue 8, 1149, Article first published online: 24 OCT 2013

  9. 35th Annual Meeting of the International Continence Society, Montreal, Canada, 28th August–2nd September 2005

    Neurourology and Urodynamics

    Volume 24, Issue 5-6, 2005, Pages: 401–598,

    Article first published online : 26 JUL 2005, DOI: 10.1002/nau.20173

  10. You have free access to this content
    Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

    BJU International

    Volume 113, Issue 6, June 2014, Pages: 951–960, Osamu Yamaguchi, Eiji Marui, Hidehiro Kakizaki, Yukio Homma, Yasuhiko Igawa, Masayuki Takeda, Osamu Nishizawa, Momokazu Gotoh, Masaki Yoshida, Osamu Yokoyama, Narihito Seki, Yasushi Ikeda and Sumito Ohkawa

    Article first published online : 17 MAR 2014, DOI: 10.1111/bju.12649

  11. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms

    BJU International

    Volume 109, Issue 12, June 2012, Pages: 1831–1840, Steven A. Kaplan, Claus G. Roehrborn, Jason Gong, Franklin Sun and Zhonghong Guan

    Article first published online : 3 OCT 2011, DOI: 10.1111/j.1464-410X.2011.10624.x

  12. You have free access to this content
    Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

    Neurourology and Urodynamics

    Volume 33, Issue 1, January 2014, Pages: 17–30, Christopher R. Chapple, Linda Cardozo, Victor W. Nitti, Emad Siddiqui and Martin C. Michel

    Article first published online : 11 OCT 2013, DOI: 10.1002/nau.22505

  13. Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist: an investigation of warning time in patients with OAB

    International Journal of Clinical Practice

    Volume 60, Issue 1, January 2006, Pages: 119–126, N. Zinner, 1 J. Susset, 2 M. Gittelman, 3 M. Arguinzoniz, 4 L. Rekeda and 5 F. Haab 6

    Article first published online : 20 DEC 2005, DOI: 10.1111/j.1368-5031.2005.00770.x

    Corrected by:

    Erratum

    Vol. 60, Issue 7, 890, Article first published online: 9 OCT 2008

  14. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo-controlled trials

    Neurourology and Urodynamics

    Volume 31, Issue 8, November 2012, Pages: 1258–1265, Catherine E. DuBeau, Jon D. Morrow, Stephen R. Kraus, Dana Creanga and Tamara Bavendam

    Article first published online : 20 AUG 2012, DOI: 10.1002/nau.22252

  15. You have free access to this content
    Efficacy of Propiverine in Improving Symptoms and Quality of Life in Female Patients with Wet Overactive Bladder

    LUTS: Lower Urinary Tract Symptoms

    Volume 1, Issue 1, June 2009, Pages: 20–24, Tomonori KOMATSU, Momokazu GOTOH, Yasuhito FUNAHASHI, Yoshihisa MATSUKAWA, Naoto SASSA, Kumiko KATO, Masashi KATO and Ryohei HATTORI

    Article first published online : 17 JUN 2009, DOI: 10.1111/j.1757-5672.2009.00006.x

  16. You have free access to this content
    Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial

    International Journal of Urology

    Volume 21, Issue 6, June 2014, Pages: 586–593, Osamu Yamaguchi, Eiji Uchida, Naruhito Higo, Hidenao Minami, Shigeo Kobayashi, Hiroyuki Sato and on behalf of the Oxybutynin Patch Study Group

    Article first published online : 18 DEC 2013, DOI: 10.1111/iju.12372

  17. Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

    LUTS: Lower Urinary Tract Symptoms

    Osamu YAMAGUCHI, Eiji MARUI, Yasuhiko IGAWA, Masayuki TAKEDA, Osamu NISHIZAWA, Yasushi IKEDA and Sumito OHKAWA

    Article first published online : 11 MAR 2014, DOI: 10.1111/luts.12053

  18. Basic science posters

    Neurourology and Urodynamics

    Volume 28, Issue 2, February 2009, Pages: 107–163,

    Article first published online : 18 FEB 2009, DOI: 10.1002/nau.20707

  19. Efficacy, Safety and Tolerability of Fesoterodine in Asian Patients with Overactive Bladder

    LUTS: Lower Urinary Tract Symptoms

    Volume 3, Issue 1, April 2011, Pages: 43–50, Osamu YAMAGUCHI, Osamu NISHIZAWA, Masayuki TAKEDA, Masaki YOSHIDA, Myung-Soo CHOO, Jeong GU LEE, Alex TONG-LONG LIN, Ho-Hsiung LIN, Wai-chun ANDREW YIP, Hitoshi ISOWA and Shintaro HIRO

    Article first published online : 7 APR 2011, DOI: 10.1111/j.1757-5672.2011.00091.x

  20. You have free access to this content
    Low-Dose Anticholinergic Combination Therapy in Male Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms

    LUTS: Lower Urinary Tract Symptoms

    Volume 4, Issue s1, March 2012, Pages: 102–109, Won Hee PARK and Hyeong GON KIM

    Article first published online : 19 MAR 2012, DOI: 10.1111/j.1757-5672.2011.00135.x